Safety and Tolerability Trial of KH631 Gene Therapy for Neovascular AMD
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects
with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and
blocks VEGF via an adeno-associated viral vector. The standard of care for patients with
neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and
reduction in fluid. A one time placement of a product which inhibits VEGF has the potential
to reduce the patient burden of regular intraocular injections.